Results 261 to 270 of about 63,333 (299)

Health‐Related Quality of Life in Relation to the 5‐2‐1 Criteria in Parkinson's Disease in Sweden

Movement Disorders Clinical Practice, Volume 12, Issue 10, Page 1511-1519, October 2025.
Abstract Background Device‐aided therapies (DAT) offer alternatives to oral or transdermal dopaminergic treatments in advanced Parkinson's disease (PD), where they can reduce motor fluctuations and dyskinesia and improve health‐related quality of life (HRQoL).
Frida Hjalte, Anna Gustafsson, Jenny Samuelsson, Filip Bergquist, Anders Johansson, Per Odin   +5 more
wiley   +1 more source

The Unseen Burden: Uncovering Shame and Its Determinants in Parkinson's Disease

Movement Disorders Clinical Practice, Volume 12, Issue 10, Page 1551-1559, October 2025.
Abstract Background Shame is frequent in Parkinson's disease (PD) and often overlooked. Objective The aim was to assess factors associated with PD‐related shame. Methods PD‐related shame was measured using the Shame and Embarrassment in PD (SPARK) scale in patients without cognitive impairment.
Sabina Catalano Chiuvé, Damien Benis, Charline Rime, Maria João Forjaz, Paul Krack, Carmen Rodriguez‐Blazquez, Vanessa Fleury   +6 more
wiley   +1 more source

Epidemiologic Disparities and Challenges in Non-parkinsonian Tremor Disorders Research: A Scoping Review Emphasizing the Indian Context

Sachin K. Udwani, Soaham Desai
openalex   +1 more source

Patterns and causes of supranuclear vertical gaze palsy: A retrospective, single-institutional study in 113 patients. [PDF]

Clin Park Relat Disord
Kern D, Raber K, Wünsch G, Schwingenschuh P.   +3 more
europepmc   +1 more source

Neuromotor rehabilitation in Parkinsonian syndromes: outcomes and disability after hip fracture. [PDF]

Eur J Med Res
Scamarcia PG, Ambrosi F, Demontis A, Huci EM, Perego S, Sanavia L, Vulpio L, Concardi G.   +7 more
europepmc   +1 more source

Compressive Cervical Myelopathy Causing Impaired Gait after Deep Brain Stimulation Is Not Rare

Movement Disorders Clinical Practice, Volume 12, Issue 10, Page 1672-1674, October 2025.
Caroline Weill, Sami Heymann, Roy Dayan, Eduard Linetsky, Hagai Bergman, Zvi Israel, David Arkadir   +6 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Neuroimaging in Parkinsonian Disorders

Neurology India, 2018
Neuroimaging (NI) in Parkinson's disease (PD) includes functional techniques like positron emission tomography (PET) and single photon emission computed tomography (SPECT), and morphological imaging using magnetic resonance imaging (MRI) and transcranial sonography to probe different aspects of the neurobiology of PD.
Atin Kumar, Chandrasekhar Bal, Madhavi Tripathi   +2 more
openaire   +2 more sources

Atypical Parkinsonian Disorders

Movement Disorders, 2005
In many neurological diseases the topography of the lesion, whatever its nature, determines the clinical signs, whereas the nature of the lesion (vascular, inflammatory, degenerative, etc.) whatever its topography, determines the time course. According to J. P. Martin (1), this general principle cannot be simply applied to diseases of the basal ganglia
Werner Poewe, Gregor K. Wenning
openaire   +4 more sources

Neuromelanin in parkinsonian disorders: an update

International Journal of Neuroscience, 2017
Neuromelanin (NM) is a dark pigment that accumulates linearly with aging in substantia nigra (SN) and locus coeruleus (LC). The dual protective and toxic role of NM has been hypothesized according to its intraneuronal or extraneuronal deposition. The melanized dopaminergic neurons in SN and LC seem to have special vulnerability to neurodegeneration in ...
Martin-bastida, Antonio, Pietracupa, Sara, Piccini, Paola   +2 more
openaire   +3 more sources

Botulinum toxin in the management of parkinsonian disorders

Toxicon, 2023
Many studies have shown that botulinum toxin (BoNT) can be an option to treat motor and non-motor symptoms in Parkinson's disease (PD) and parkinsonian syndromes. The advantages of BoNT compared to oral medications include localized action and low incidence of systemic side effects, which is important in treating neurodegenerative disease.
Talyta Grippe, Robert Chen
openaire   +2 more sources